Your browser is no longer supported. Please, upgrade your browser.
Settings
KIN Kindred Biosciences, Inc. daily Stock Chart
KIN [NASD]
Kindred Biosciences, Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own6.20% Shs Outstand33.35M Perf Week-2.95%
Market Cap372.52M Forward P/E- EPS next Y-1.46 Insider Trans-10.52% Shs Float31.66M Perf Month-8.89%
Income-44.00M PEG- EPS next Q-0.44 Inst Own66.90% Short Float1.40% Perf Quarter-6.13%
Sales0.60M P/S620.87 EPS this Y-8.70% Inst Trans0.11% Short Ratio2.61 Perf Half Y-6.92%
Book/sh3.11 P/B3.59 EPS next Y7.60% ROA-43.30% Target Price23.50 Perf Year26.21%
Cash/sh2.75 P/C4.07 EPS next 5Y40.00% ROE-46.20% 52W Range7.55 - 15.75 Perf YTD2.01%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.08% Beta0.85
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin82.80% 52W Low47.95% ATR0.55
Employees63 Current Ratio10.80 Sales Q/Q- Oper. Margin- RSI (14)44.34 Volatility4.20% 4.90%
OptionableYes Debt/Eq0.00 EPS Q/Q-34.70% Profit Margin- Rel Volume0.77 Prev Close11.23
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume170.14K Price11.17
Recom2.00 SMA200.10% SMA50-9.76% SMA200-6.18% Volume131,512 Change-0.53%
Nov-08-18Reiterated B. Riley FBR Buy $16 → $21
Jul-24-18Initiated Cantor Fitzgerald Overweight
Dec-27-17Initiated CL King Neutral
Nov-20-17Resumed B. Riley FBR, Inc. Buy $11
Nov-17-17Initiated H.C. Wainwright Buy $9.50
May-24-17Initiated FBR & Co. Outperform $10
Nov-01-16Initiated Ladenburg Thalmann Buy $7.50
Jan-24-14Downgrade BMO Capital Markets Outperform → Market Perform $15
Jan-14-19 07:01AM  Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital PR Newswire
Nov-16-18 08:35AM  Recent Analysis Shows Spirit Airlines, Cactus, Evergy, ADDvantage Technologies Group, Kindred Biosciences, and Farfetch Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-14-18 01:36AM  Edited Transcript of KIN earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 04:01PM  Kindred Biosciences Announces Third Quarter 2018 Financial Results PR Newswire
Oct-30-18 04:01PM  Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent PR Newswire
Oct-24-18 08:31AM  Kindred Biosciences to Announce Third Quarter 2018 Financial Results PR Newswire -6.24%
Oct-23-18 07:31AM  Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President PR Newswire
Sep-17-18 08:31AM  Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference PR Newswire
Aug-30-18 08:31AM  Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit PR Newswire
Aug-26-18 11:55PM  Edited Transcript of KIN earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-21-18 08:31AM  Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference PR Newswire
Aug-09-18 04:01PM  Kindred Biosciences Announces Second Quarter 2018 Financial Results PR Newswire
Jul-16-18 08:31AM  Kindred Biosciences to Announce Second Quarter 2018 Financial Results PR Newswire
Jul-09-18 08:31AM  Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States PR Newswire
Jun-26-18 05:55PM  [$$] Kindred Biosciences' Top Holder Buys $8M More in Stock Barrons.com
Jun-25-18 09:01AM  Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock PR Newswire
Jun-20-18 04:01PM  Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program PR Newswire
09:10AM  Kindred Biosciences Announces Pricing of Public Offering PR Newswire
Jun-19-18 04:01PM  Kindred Biosciences Announces Proposed Public Offering of Common Stock PR Newswire
May-31-18 06:46AM  Who Owns Most Of Prima Park SA. (WSE:KIN)? Simply Wall St.
May-30-18 07:02AM  KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses PR Newswire
May-29-18 08:02AM  Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference PR Newswire
May-24-18 07:02AM  Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference PR Newswire
May-14-18 01:41AM  Edited Transcript of KIN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 09:10AM  Unlocking The Value In Animal Medicine Forbes
May-09-18 07:05AM  Blog Exposure - Kindred Biosciences Gets FDA Approval for Mirataz ACCESSWIRE
May-08-18 04:01PM  Kindred Biosciences Announces First Quarter 2018 Financial Results PR Newswire
10:15AM  Is Prima Park SA. (WSE:KIN) A Financially Sound Company? Simply Wall St.
May-07-18 04:43PM  This Peninsula company's new drug is the cat's meow the FDA says so American City Business Journals
09:11AM  Weight Gain Season for Felines The Wall Street Journal
07:00AM  Kindred Biosciences Receives FDA Approval of Mirataz (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats PR Newswire
Apr-25-18 04:02PM  Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors PR Newswire
Apr-24-18 04:02PM  Kindred Biosciences Provides Updates on Pending Drug Approvals PR Newswire
Apr-18-18 04:01PM  Kindred Biosciences to Announce First Quarter 2018 Financial Results PR Newswire
Mar-08-18 04:01PM  Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference PR Newswire
Mar-02-18 02:16PM  Edited Transcript of KIN earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-18 04:01PM  Kindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial Results PR Newswire
12:30PM  Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 08:30AM  Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results PR Newswire
Feb-13-18 08:30AM  Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit PR Newswire
Dec-21-17 08:02AM  KindredBio Announces Submission of European Medicines Agency Filing for Mirataz PR Newswire
Dec-04-17 08:02AM  KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses PR Newswire
Nov-19-17 08:51PM  Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 05:27PM  Kindred Bio reports 3Q loss Associated Press
04:01PM  Kindred Biosciences Announces Third Quarter 2017 Financial Results PR Newswire
10:40AM  Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Oct-11-17 09:01AM  Kindred Biosciences to Announce Third Quarter 2017 Financial Results PR Newswire
Oct-05-17 04:01PM  Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference PR Newswire
Sep-11-17 09:00AM  Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof PR Newswire
Aug-30-17 09:02AM  Kindred Biosciences to Present at Upcoming Investor Conferences PR Newswire
Aug-12-17 05:40AM  Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-17 11:58PM  Kindred Bio reports 2Q loss Associated Press
04:01PM  Kindred Biosciences Announces Second Quarter 2017 Financial Results PR Newswire
06:40AM  Investor Network: Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-04-17 09:02AM  Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting PR Newswire
Aug-01-17 08:34AM  Liolios 6th Annual Gateway Conference to Showcase 100 Companies at the Four Seasons San Francisco on September 6-7 GlobeNewswire
Jul-24-17 09:01AM  Kindred Biosciences to Announce Second Quarter 2017 Financial Results PR Newswire
Jul-20-17 09:30AM  Zacks.com featured highlights: Logitech International, Herman Miller, Diodes, Willdan Group and Kindred Biosciences Zacks
Jul-12-17 08:56AM  Kindred Biosciences' stock drops after public stock offering MarketWatch
08:40AM  KindredBio Announces Pricing of Public Offering PR Newswire
Jul-11-17 04:10PM  KindredBio Announces Proposed Public Offering of Common Stock PR Newswire -7.65%
Jun-30-17 06:14AM  Will Kindred Biosciences (KIN) Continue to Surge Higher? Zacks -7.03%
Jun-26-17 07:30AM  Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta PR Newswire
Jun-15-17 08:01AM  Kindred Biosciences Added to the Russell 2000 Index PR Newswire
May-30-17 09:01AM  Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference PR Newswire
May-24-17 09:01AM  Kindred Biosciences to Present at 7th Annual LD Micro Invitational PR Newswire
May-11-17 07:46AM  Edited Transcript of KIN earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-03-17 05:09PM  Kindred Bio reports 1Q loss Associated Press
04:01PM  Kindred Biosciences Announces First Quarter 2017 Financial Results PR Newswire
08:15AM  Investor Network: Kindred Biosciences, Inc. to Host Earnings Call Accesswire
May-01-17 07:02AM  Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses PR Newswire
Apr-24-17 08:32AM  Kindred Biosciences to Announce First Quarter 2017 Financial Results PR Newswire
Mar-16-17 04:01PM  Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit PR Newswire
Mar-08-17 01:04PM  KINDRED BIOSCIENCES, INC. Financials
Mar-07-17 08:30AM  Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology PR Newswire
Mar-01-17 04:18PM  Kindred Bio reports 4Q loss Associated Press
04:08PM  KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:01PM  Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Kindred Biosciences Inc Earnings Release - After Market Close
Feb-21-17 08:30AM  Kindred Biosciences to Announce Fourth Quarter and Year-End 2016 Financial Results PR Newswire
Feb-06-17 09:00AM  Kindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz New Animal Drug Application PR Newswire
Jan-22-17 10:25AM  Insider Buying Slows as Trump Inauguration Takes Center Stage: Kindred Biosciences, Mirati Therapeutics, City Office REIT and More 24/7 Wall St.
Jan-19-17 12:55PM  These Insiders Are Still Finding Some Good Value in the Stock Market TheStreet.com
12:55PM  These Insiders Are Still Finding Some Good Value in the Stock Market
Jan-16-17 08:45AM  Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5% Zacks
Jan-06-17 08:07AM  KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Dec-28-16 01:00PM  The 2017 Gad Value Investment Fund, Part 2
Dec-19-16 04:34PM  KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-14-16 06:07AM  Digirad Corporation (DRAD): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-07-16 02:25PM  KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Dec-05-16 11:36AM  Kindred Biosciences, Inc. :KIN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
Nov-29-16 09:01AM  Kindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine Practitioners Convention PR Newswire
Nov-18-16 09:01AM  Kindred Biosciences to Present at 9th Annual LD Micro Investor Conference PR Newswire
Nov-07-16 04:19PM  KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:09AM  Kindred Bio reports 3Q loss
09:01AM  Kindred Biosciences Announces Third Quarter 2016 Financial Results PR Newswire
07:07AM  Q3 2016 Kindred Biosciences Inc Earnings Release - After Market Close
Nov-01-16 11:25AM  Kindred Biosciences Is 'Setting The Pace In Animal Health Biologics'
06:49AM  Coverage initiated on Kindred Biosciences by Ladenburg Thalmann
Oct-24-16 09:01AM  Kindred Biosciences to Announce Third Quarter 2016 Financial Results PR Newswire
Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chin RichardChief Executive OfficerJan 02Sale10.5740,000422,7161,906,071Jan 04 08:41 PM
Chin RichardChief Executive OfficerDec 03Sale13.2840,000531,2001,946,071Dec 04 07:00 PM
Chin RichardCEONov 01Sale14.6840,000587,2001,986,071Nov 02 07:47 PM
MARIO ERNESTDirectorOct 29Option Exercise3.4144,833152,941169,000Oct 31 06:56 PM
Chin RichardPresident and CEOOct 01Sale13.2840,000531,2002,026,071Oct 03 05:15 PM
Townsend RaymondDirectorSep 26Sale13.302,88538,37124,928Sep 27 08:49 PM
Townsend RaymondDirectorSep 25Sale13.801151,58727,813Sep 27 08:49 PM
Chin RichardPRESIDENT AND CEOSep 05Sale14.697,600111,6442,066,071Sep 06 08:07 PM
Chin RichardPRESIDENT AND CEOSep 04Sale14.8132,400479,8442,073,671Sep 06 08:07 PM
Chin RichardPresident and CEOAug 01Sale13.5140,000540,4002,106,071Aug 03 09:06 PM
Chin RichardPresident and CEOJul 02Sale10.2840,000411,2002,146,071Jul 03 05:57 PM
Park West Asset Management LLC10% OwnerJun 20Buy9.50845,2628,029,9896,002,053Jun 22 04:48 PM
Chin RichardPresident and CEOJun 01Sale10.1340,000405,2002,186,071Jun 01 07:07 PM
Chin RichardPresident and CEOMay 30Sale10.0012,610126,1002,226,071Jun 01 07:07 PM
Chin RichardPresident and CEOMay 25Sale10.003,00030,0002,238,681May 29 07:48 PM
Chin RichardPresident and CEOMay 24Sale10.00606002,241,681May 29 07:48 PM
Chin RichardPresident and CEOMay 18Sale10.002,40024,0002,241,741May 18 06:35 PM
Chin RichardPresident and CEOMay 09Sale10.002002,0002,244,141May 09 07:28 PM
Chin RichardPresident and CEOMay 07Sale10.011,73017,3172,244,341May 09 07:28 PM
Chin RichardPresident and CEOMay 01Sale9.0520,000181,0002,246,071May 02 08:34 PM
Chin RichardPresident and CEOApr 02Sale8.3920,000167,8002,266,071Apr 04 07:08 PM
Townsend RaymondDirectorMar 16Option Exercise3.452,4888,58427,928Mar 19 06:41 PM
Townsend RaymondDirectorMar 16Sale9.459108,60026,350Mar 19 06:41 PM
Townsend RaymondDirectorMar 15Option Exercise3.454,81316,60526,350Mar 19 06:41 PM
Townsend RaymondDirectorMar 15Sale9.451,76016,63223,297Mar 19 06:41 PM
Townsend RaymondDirectorMar 12Option Exercise3.4524684923,297Mar 14 08:32 PM
Townsend RaymondDirectorMar 12Sale9.459186023,142Mar 14 08:32 PM